Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 24, 2023 05:18 ET | Source: Research and Markets

Outlook on the SYK Inhibitors Global Market to 2028 - Players Include Calithera Biosciences, CrystalGenomics, CSPC Ouyi Pharmaceutical, Genosco and Hanmi Pharmaceutical

Dublin, Feb. 24, 2023 (GLOBE NEWSWIRE) -- The "Global SYK Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. This report contains a...
September 09, 2022 07:03 ET | Source: Research and Markets

Global Clinical Trial Kits Market (2022 to 2030) - Featuring Almac, Alpha Laboratories and Brooks Life Science Among Others

Dublin, Sept. 09, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trial Kits Market Share, Size, Trends, Industry Analysis Report, By Service , By Phase , By Region; Segment Forecast, 2022 - 2030" report has...
August 08, 2022 06:33 ET | Source: Research and Markets

Global TIM3 Inhibitors Drug Clinical Trials & Market Opportunities Report 2022: Market to Surpass $1 Billion by 2028, Driven by the First Drug Approval Expected to be Launched by 2024

Dublin, Aug. 08, 2022 (GLOBE NEWSWIRE) -- The "TIM3 Inhibitors Drug Clinical Trials & Market Opportunity Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global...
March 28, 2022 04:13 ET | Source: Research and Markets

Global Clinical Trials Markets Report 2022: In 2020, IQVIA Dominated the Market, Followed by PPD, Syneos Health, PRA Health Sciences, and LabCorp - Forecast to 2026

Dublin, March 28, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy...
January 13, 2022 10:38 ET | Source: AI Therapeutics, Inc.

AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS

GUILFORD, Conn., Jan. 13, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, announced today the initiation...
October 02, 2018 00:00 ET | Source: Factor Therapeutics

Shareholder Update Q3 2018

Highlights: Venous leg ulcer Phase 2 trial on track: top-line results mid-NovemberDiabetic foot ulcer pilot clinical study: in development with key US researchersOcular wounds: international patent...
September 05, 2018 20:00 ET | Source: Factor Therapeutics

Phase 2 Clinical Trial for Venous Leg Ulcers Nears Completion

BRISBANE, Australia, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX: FTT, the “Company”), an Australian biomedical company developing therapeutics for advanced wound care, is...
August 20, 2018 08:19 ET | Source: Taiwan Liposome Company, Ltd.

Taiwan Liposome Company Reports Positive Top-Line Data from Phase II Clinical Trial of TLC599 in Knee Osteoarthritis Pain

Primary endpoint and key secondary endpoints metTLC599 demonstrated statistically significant improvement over placebo through Weeks 12, 16, 20, and 24 TLC599 was well-tolerated with no...
December 20, 2016 09:00 ET | Source: Factor Therapeutics

Factor Therapeutics Announces Commencement of Phase II Trial of a Novel Topical Biologic for the Treatment of Chronic Wounds

BRISBANE, Australia, Dec. 20, 2016 (GLOBE NEWSWIRE) -- Factor Therapeutics Limited (ASX:FTT) is pleased to announce that it has enrolled the first patient for its US multi-centre Phase II trial of...

keyboard_arrow_left Previous Page